Factor VII-activating protease promotes the proteolysis and inhibition of tissue factor pathway inhibitor

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 2, 2012, Pages 427-433

  Kanse, Sandip M ^a,b   Declerck, Paul J ^c   Ruf, Wolfram ^d   Broze, George ^e   Etscheid, Michael ^f  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f PAUL EHRLICH INSTITUT   (Germany)

Author keywords

atherosclerosis; hemostasis; thrombosis; vascular biology

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7 ACTIVATING PROTEASE; MONOCLONAL ANTIBODY; PROTEINASE; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC VARIABILITY; HEMOSTASIS; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION;

ANTIBODIES, MONOCLONAL; CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HEMOSTASIS; HUMANS; LIPOPROTEINS; PROTEOLYSIS; SERINE ENDOPEPTIDASES;

EID: 84856235806     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.238394     Document Type: Article

References (36)

1. Romisch J, Feussner A, Vermohlen S, Stohr HA. A protease isolated from human plasma activating factor VII independent of tissue factor. Blood Coagul Fibrinolysis. 1999;10:471-479.
2. Romisch J, Vermohlen S, Feussner A, Stohr H. The FVII activating protease cleaves single-chain plasminogen activators. Haemostasis. 1999; 29:292-299.
3. Yamamichi S, Nishitani M, Nishimura N, Matsushita Y, Hasumi K. Polyamine-promoted autoactivation of plasma hyaluronan-binding protein, a serine protease involved in extracellular proteolysis. J Thromb Haemost. 2010;8:559-566.
4. Kanse SM, Etscheid M. Factor VII activating protease (FSAP): caught in the crossfire between polyanions and polycations. J Thromb Haemost. 2010;8:556-559.
5. Stephan F, Hazelzet JA, Bulder I, Boermeester MA, van Till JO, van der Poll T, Wuillemin WA, Aarden LA, Zeerleder S. Activation of factor VII-activating protease in human inflammation: a sensor for cell death. Crit Care. 2011;15:R110.
6. Yamamichi S, Fujiwara Y, Kikuchi T, Nishitani M, Matsushita Y, Hasumi K. Extracellular histone induces plasma hyaluronan-binding protein (factor VII activating protease) activation in vivo. Biochem Biophys Res Commun. 2011;409:483-488.
7. Muller F, Mutch NJ, Schenk WA, Smith SA, Esterl L, Spronk HM, Schmidbauer S, Gahl WA, Morrissey JH, Renne T. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell. 2009;139:1143-1156.
8. Romisch J. Factor VII activating protease (FSAP): a novel protease in hemostasis. Biol Chem. 2002;383:1119-1124.
9. Hoppe B, Tolou F, Radtke H, Kiesewetter H, Dorner T, Salama A. Marburg I polymorphism of factor VII-activating protease is associated with idiopathic venous thromboembolism. Blood. 2005;105:1549-1551.
10. van Minkelen R, de Visser MC, Vos HL, Bertina RM, Rosendaal FR. The Marburg I polymorphism of factor VII-activating protease is not associated with venous thrombosis. Blood. 2005;105:4898; author reply 4899.
11. Gulesserian T, Hron G, Endler G, Eichinger S, Wagner O, Kyrle PA. Marburg I polymorphism of factor VII-activating protease and risk of recurrent venous thromboembolism. Thromb Haemost. 2006;95:65-67.
12. Franchi F, Martinelli I, Biguzzi E, Bucciarelli P, Mannucci PM. Marburg I polymorphism of factor VII-activating protease and risk of venous thromboembolism. Blood. 2006;107:1731.
13. Pecheniuk NM, Elias DJ, Xu X, Griffin JH. Failure to validate association of gene polymorphisms in EPCR, PAR-1, FSAP and protein S Tokushima with venous thromboembolism among Californians of European ancestry. Thromb Haemost. 2008;99:453-455.
14. Weisbach V, Ruppel R, Eckstein R. The Marburg I polymorphism of factor VII-activating protease and the risk of venous thromboembolism. Thromb Haemost. 2007;97:870-872.
15. Reiner AP, Lange LA, Smith NL, Zakai NA, Cushman M, Folsom AR. Common hemostasis and inflammation gene variants and venous thrombosis in older adults from the Cardiovascular Health Study. J Thromb Haemost. 2009;7:1499-1505.
16. Willeit J, Kiechl S, Weimer T, Mair A, Santer P, Wiedermann CJ, Roemisch J. Marburg I polymorphism of factor VII-activating protease: a prominent risk predictor of carotid stenosis. Circulation. 2003;107:667-670.
17. Ireland H, Miller GJ, Webb KE, Cooper JA, Humphries SE. The factor VII activating protease G511E (Marburg) variant and cardiovascular risk. Thromb Haemost. 2004;92:986-992.
18. Trompet S, Pons D, Kanse SM, de Craen AJM, Ikram MA, Verschuren JJW, Zwinderman AH, Doevendans PAFM, Tio RA, Winters RB, Slagboom PE, Westendorp RGJ, Jukema JW. Factor VII activating protease (FSAP) polymorphism (G534E) is associated with increased risk for stroke and mortality. Stroke Res Treat. 2011;2011:424759.
19. Wasmuth HE, Tag CG, Van de Leur E, Hellerbrand C, Mueller T, Berg T, Puhl G, Neuhaus P, Samuel D, Trautwein C, Kanse SM, Weiskirchen R. The Marburg I variant (G534E) of the factor VII-activating protease determines liver fibrosis in hepatitis C infection by reduced proteolysis of platelet-derived growth factor BB. Hepatology. 2009;49:775-780.
20. Sedding D, Daniel JM, Muhl L, Hersemeyer K, Brunsch H, Kemkes-Matthes B, Braun-Dullaeus RC, Tillmanns H, Weimer T, Preissner KT, Kanse SM. The G534E polymorphism of the gene encoding the factor VII-activating protease is associated with cardiovascular risk due to increased neointima formation. J Exp Med. 2006;203:2801-2807.
21. Crawley JT, Lane DA. The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol. 2008;28:233-242.
22. Lupu C, Poulsen E, Roquefeuil S, Westmuckett AD, Kakkar VV, Lupu F. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol. 1999;19:2251-2262.
23. Maroney SA, Ellery PE, Mast AE. Alternatively spliced isoforms of tissue factor pathway inhibitor. Thromb Res. 2011;125(suppl 1):S52-S56.
24. Kothari H, Kaur G, Sahoo S, Idell S, Rao LV, Pendurthi U. Plasmin enhances cell surface tissue factor activity in mesothelial and endothelial cells. J Thromb Haemost. 2009;7:121-131.
25. Ohkura N, Enjyoji K, Kamikubo Y, Kato H. A novel degradation pathway of tissue factor pathway inhibitor: incorporation into fibrin clot and degradation by thrombin. Blood. 1997;90:1883-1892.
26. Higuchi DA, Wun TC, Likert KM, Broze GJ Jr The effect of leukocyte elastase on tissue factor pathway inhibitor. Blood. 1992;79:1712-1719.
27. Schuepbach RA, Velez K, Riewald M. Activated protein C up-regulates procoagulant tissue factor activity on endothelial cells by shedding the TFPI Kunitz 1 domain. Blood. 2011;117:6338-6346.
28. Singh R, Pan S, Mueske CS, Witt T, Kleppe LS, Peterson TE, Slobodova A, Chang JY, Caplice NM, Simari RD. Role for tissue factor pathway in murine model of vascular remodeling. Circ Res. 2001;89:71-76.
29. Massberg S, Grahl L, von Bruehl ML, Manukyan D, Pfeiler S, Goosmann C, Brinkmann V, Lorenz M, Bidzhekov K, Khandagale AB, Konrad I, Kennerknecht E, Reges K, Holdenrieder S, Braun S, Reinhardt C, Spannagl M, Preissner KT, Engelmann B. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med. 2010;16:887-896.
30. Han X, Girard TJ, Baum P, Abendschein DR, Broze GJ Jr Structural requirements for TFPI-mediated inhibition of neointimal thickening after balloon injury in the rat. Arterioscler Thromb Vasc Biol. 1999;19:2563-2567.
31. Sandset PM, Larsen ML, Abildgaard U, Lindahl AK, Odegaard OR. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol. Blood Coagul Fibrinolysis. 1991;2:425-433.
32. Bognacki J, Hammelburger J. Functional and immunologic methods for the measurement of human tissue factor pathway inhibitor. Blood Coagul Fibrinolysis. 1995;6(suppl 1):S65-S72.
33. Altincicek B, Shibamiya A, Trusheim H, Tzima E, Niepmann M, Linder D, Preissner KT, Kanse SM. A positively charged cluster in the epidermal growth factor-like domain of Factor VII-activating protease (FSAP) is essential for polyanion binding. Biochem J. 2006;394:687-692.
34. Pan S, White TA, Witt TA, Chiriac A, Mueske CS, Simari RD. Vasculardirected tissue factor pathway inhibitor overexpression regulates plasma cholesterol and reduces atherosclerotic plaque development. Circ Res. 2009;105:713-720, 8 p following 720.
35. Belting M, Ahamed J, Ruf W. Signaling of the tissue factor coagulation pathway in angiogenesis and cancer. Arterioscler Thromb Vasc Biol. 2005;25:1545-1550.
36. Uusitalo-Jarvinen H, Kurokawa T, Mueller BM, Andrade-Gordon P, Friedlander M, Ruf W. Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis. Arterioscler Thromb Vasc Biol. 2007;27:1456-1462.